Regenerative medicine in cardiothoracic surgery: do the benefits outweigh the risks?

Aging is a physiologic event caused by a decline in regenerative potential mainly explained by modifications in growth factors, accumulation of DNA damage, and reduced stem cell responsiveness to external and internal stimuli (1).

The activation of aged muscle progenitor cells—that stimulate myoblasts to fuse and form new myotubes—can be restored by forced activation of the Notch signaling pathway, thereby clearly demonstrating that the intrinsic regenerative potential of old stem cells remains intact (2).

Pregnancy has been demonstrated to improve liver regeneration and remyelinate white matter lesions in aged mice, supporting the idea that pregnancy has a rejuvenating effect on the regenerative potential of several organs (3,4).

These initial intriguing experimental results in the field of rejuvenating and regenerative medicine have given rise to a considerable body of research during the last ten years. Much analysis has focused on the clinical perspectives of stem cell technologies in different fields of medicine and surgery, cardiothoracic surgery being one of the most explored but with more controversial results (5).

On the one hand, regenerative medicine applications are already a clinical reality in fields like orthopedics, dentistry and plastic surgery (6-9). On the other, their clinical benefits elsewhere, as in cardiac regeneration, remain unclear and highly debated (10).

In 2001, Orlic et al. reported that bone marrow stem cells injected into the infarcted myocardium of rodents dramatically regenerated the cardiac muscle, suggesting that a similar experimental approach could be used in clinical settings to regenerate damaged human hearts (11). Unfortunately, although some randomized clinical trials disclosed a functional improvement due to bone marrow-derived stem cells (12,13), the initial enthusiasm for heart regeneration by stem cell transplantation has since been dampened by the modest clinical benefits observed to date (10). Nowadays, the emerging concept at the basis of cardiac regeneration is that injected stem cells do not persist for long in the myocardium and do not work through a transdifferentiation process into new cardiomyocytes but rather through paracrine effectors (14).

Several critical issues have yet to be resolved in the field of cardiac regeneration by stem cell activity. First, the newly regenerated cardiomyocytes may not couple with the pre-existing cardiac cell population, leading to electric cellular conflicts culminating in arrhythmias (15). Second, the clinical use of embryonic stem cells or induced pluripotent stem cells raises major concerns because of the possibility of cancer tissue developing in the injected host (16).

Similar oncologic concerns exist in the field of airway and lung regeneration, where tumors are much more common than in cardiac surgery, thereby enhancing the risk of cancer cells being boosted by stem cell implantation (17). Following a preliminary experience on a large animal model (18), we performed the first autologous endoscopic bone marrow-derived mesenchymal stromal cell transplant to close a bronchopleural fistula developing after right extrapleural pneumonectomy (19). Some oncologic doubts were subsequently expressed claiming the use of mesenchymal stem cells in tumor excision sites may promote residual tumor growth and metastasis (17). Based on the long-term follow-up, clinical experience and the cell manufacturing techniques, the only clear contraindication to mesenchymal stromal cell topic injection remains local residual tumor (20).

Thanks to the enormous progress made in stem cell technologies and biomaterials, several prototypes of bioengineered tracheal grafts have been described (21-24), but the attractive concept of bioengineered tracheal replacements has not yielded a definitive and reliable solution (25). In fact, scientific papers in the field of stem cell research are retracted 2.4 times more often than the average for biomedicine. Although the proportion of retracted articles is still very low (about 1 out of every 1,900 papers), over half of these retractions are due to fraud (26).

In conclusion, the clinical application of successful regenerative medicine principles and stem cell technologies to daily cardiothoracic practice remains an intriguing and promising field. However, clear warnings are needed against sensational or enthusiastic reports that jeopardize the complex field of regenerative medicine making it even more dangerous and controversial.

In this spirit we invited our most prominent colleagues to contribute to this special issue on regenerative medicine in cardiothoracic surgery. The aim is to foster high-quality research in this burgeoning field, while shielding it from inappropriate applications.

Acknowledgements

None.

References

1. Falick Michaeli T, Laufer N, Sagiv JY, et al. The rejuvenating effect of pregnancy on muscle regeneration. Aging Cell 2015;14:698-700. [Crossref] [PubMed]
2. Conboy IM, Conboy MJ, Wagers AJ, et al. Rejuvenation of aged progenitor cells by exposure to a young systemic environment. Nature 2005;433:760-4. [Crossref] [PubMed]
3. Gielchinsky Y, Laufer N, Weitman E, et al. Pregnancy restores the regenerative capacity of the aged liver via activation of an mTORC1-controlled hyperplasia/hypertrophy switch. Genes Dev 2010;24:543-8. [Crossref] [PubMed]
4. Gregg C, Shikar V, Larsen P, et al. White matter plasticity and enhanced remyelination in the maternal CNS. J Neurosci 2007;27:1812-23. [Crossref] [PubMed]
5. Petrella F, Rizzo S, Borri A, et al. Current Perspectives in Mesenchymal Stromal Cell Therapies for Airway Tissue Defects. Stem Cells Int 2015;2015. [Crossref] [PubMed]
6. Chiari C, Walzer S, Stelzeneder D, et al. Therapeutic utilization of stem cells in orthopedics. Orthopade 2017;46:1077-90. [Crossref] [PubMed]
7. Ireland H, Gay MHP, Baldomero H, et al. The survey on cellular and tissue-engineered therapies in Europe and neighboring Eurasian countries in 2014 and 2015. Cytotherapy 2018;20:1-20. [Crossref] [PubMed]
8. Mata M, Milian L, Oliver M, et al. “In Vivo” Articular Cartilage Regeneration Using Human Dental Pulp Stem Cells Cultured in an Alginate Scaffold: A Preliminary Study. Stem Cells Int 2017;2017. [Crossref] [PubMed]
9. Nilforoushzadeh MA, Sisakht MM, Seifalian AM, et al. Regenerative Medicine Applications in Wound Care. Curr Stem Cell Res Ther 2017;12:658-74. [Crossref] [PubMed]
10. van Berlo JH, Molkentin JD. An emerging consensus on cardiac regeneration. Nat Med 2014;20:1386-93. [Crossref] [PubMed]
11. Orlic D, Kajstura J, Chimenti S, et al. Bone marrow cells regenerate infarcted myocardium. Nature 2001;410:701-5. [Crossref] [PubMed]
12. Assmus B, Honold J, Schächinger V, et al. Transcoronary transplantation of progenitor cells after myocardial infarction. N Engl J Med 2006;355:1222-32. [Crossref] [PubMed]
13. Assmus B, Leistner DM, Schächinger V, et al. REPAIR-AMI Study Group Long-term clinical outcome after intracoronary application of bone marrow-derived mononuclear cells for acute myocardial infarction: migratory capacity of administered cells determines event-free survival. Eur Heart J 2014;35:1275-83. [Crossref] [PubMed]
14. Loffredo FS, Steinhauser ML, Gannon J, et al. Bone marrow-derived cell therapy stimulates endogenous cardiomyocyte progenitors and promotes cardiac repair. Cell Stem Cell 2011;8:389-98. [Crossref] [PubMed]
15. Anderson ME, Goldhaber J, Houser SR, et al. Embryonic stem cell-derived cardiac myocytes are not ready for human trials. Circ Res 2014;115:335-8. [Crossref] [PubMed]
16. Ohnishi K, Semi K, Yamamoto T, et al. Premature termination of reprogramming in vivo leads to cancer development through altered epigenetic regulation. Cell 2014;156:663-77. [Crossref] [PubMed]
17. Spartalis E, Moris D, Dimitroulis D, et al. Postresectional Airway Fistula Occlusion via Stem-Cell Transplantation: Is It Oncologically Safe? Ann Thorac Surg 2015;100:2413-4. [Crossref] [PubMed]
18. Petrella F, Spaggiari L, Acocella F, et al. Airway fistula closure after stem-cell infusion. N Engl J Med 2015;372:96-7. [Crossref] [PubMed]
19. Petrella F, Toffalorio F, Brizzola S, et al. Stem cell transplantation effectively occludes bronchopleural fistula in an animal model. Ann Thorac Surg 2014;97:480-3. [Crossref] [PubMed]
20. Petrella F, Spaggiari L. Reply: To PMID 24370201. Ann Thorac Surg 2015;100:2414.
21. Petrella F, Spaggiari L. Repair of large airway defects with bioprosthetic materials. J Thorac Dis 2017;9:3674-6. [Crossref] [PubMed]
22. Udelsman BV, Eaton J, Muniappan A, et al. Repair of large airway defects with bioprosthetic materials. J Thorac Cardiovasc Surg 2016;152:1388-97. [Crossref] [PubMed]
23. Aho JM, Dietz AB, Radel DJ, et al. Closure of a Recurrent Bronchopleural Fistula Using a Matrix Seeded With Patient-Derived Mesenchymal Stem Cells. Stem Cells Transl Med 2016;5:1375-9. [Crossref] [PubMed]
24. Macchiarini P, Jungebluth P, Go T, et al. Clinical transplantation of a tissue-engineered airway. Lancet 2008;372:2023-30. [Crossref] [PubMed]
25. Sjöqvist S, Jungebluth P, Lim ML, et al. Editorial Expression of Concern: Experimental orthotopic transplantation of a tissue-engineered oesophagus in rats. Nat Commun 2016;7:13310. [Crossref] [PubMed]
26. Are retractions more frequent in stem cell research? Available online: (last accessed on October, 22, 2017).http://retractionwatch.com/2015/02/26/are-retractions-more-frequent-in-stem-cell-research/

Francesco Petrella